Lilly CEO calls Medicare obesity coverage a 'game changer' for orforglipron launch
Medicare is set to cover obesity drugs for the first time later this year, and Lilly's CEO says that access, more than price alone, could shape how many patients try its experimental pill.
Eli Lilly CEO Dave Ricks said on Jan. 30 that Medicare coverage of obesity drugs could be a "game changer" for the launch of the company's experimental obesity pill, orforglipron, describing the coming coverage as a major catalyst for the rollout [1].
Lilly is preparing for a "full launch" of orforglipron in the second quarter of this year, and Ricks said the company expects Medicare coverage for the treatment "immediately following that launch, and that will change the game a bit too" [1]. The pill is still experimental, and its approval status was not addressed in the interview [1].
Medicare is set to start covering obesity medicines for the first time later this year under drug pricing deals that Lilly and Novo Nordisk struck with President Donald Trump in November [1]. Under those deals, certain Medicare patients will pay a $50 monthly copay for all approved uses of injectable and oral GLP-1 drugs, including diabetes and obesity treatment [1]. Ricks estimated that 20 million to 30 million Medicare beneficiaries who have obesity and related health conditions could be eligible for GLP-1 treatments, calling the coverage "a big multiplier on the eligible pool" [1].
Novo Nordisk's Wegovy pill for obesity launched earlier this month and is "off to a strong start" even with spotty insurance coverage, and many patients are paying cash for it [1]. Ricks said he noticed that nearly all of the early adopters of Novo's pill are new to GLP-1 treatments rather than users of existing injections, so "it's expansive, it's reaching more patients and that's great" [1].
On pricing, Ricks acknowledged there will be "a step down in pricing" early this year under the deals, and said volume growth of Lilly's drugs "will ramp on the back half of the year" [1]. He said Lilly will share more detail on the financial impact when it reports fourth-quarter earnings and 2026 guidance the following week [1]. The agreements also include commitments to sell drugs at discounted cash-pay prices on Trump's direct-to-consumer platform, TrumpRx, which was expected to launch in January but is not yet live [1]. Ricks said Lilly was the first drugmaker to sell obesity treatments directly to patients through its own platform, LillyDirect, and that TrumpRx expands that approach across the industry [1].
Why it matters for patients
For people on Medicare, the practical change is that obesity treatment could be covered rather than paid for entirely in cash. Under the pricing deals, certain Medicare patients will pay a $50 monthly copay for approved GLP-1 drugs across diabetes and obesity uses [1]. Ricks said he expects coverage for orforglipron right after its launch [1]. Health experts have said Medicare coverage could broaden the market for these medicines and prompt more private insurers to cover them [1].
Several things are not yet known. Whether orforglipron will be approved for obesity treatment, what it would cost without insurance, the exact date Medicare coverage begins, and whether coverage would include orforglipron at the time of launch were not reported in the interview [1]. Ricks' figure of 20 million to 30 million eligible Medicare beneficiaries is his own estimate, not an official count [1].
What happens next
Lilly plans to report fourth-quarter earnings and 2026 guidance the week after Jan. 30, which Ricks said will include more detail on the financial impact of the pricing deals [1]. Ricks said Lilly is preparing a full launch of orforglipron in the second quarter [1]. Medicare coverage of obesity medicines is expected later this year, with no specific start date reported [1]. TrumpRx, the direct-to-consumer site tied to the deals, had been expected to launch in January and is not yet live [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.